Dr. Papagiannakopoulos’s research is pioneering in its examination of how cancer cells adapt metabolically to stressful environments, rewiring nutrient and energy utilization pathways to survive and evade immune destruction. His laboratory employs sophisticated genome editing tools and functional genetic screens in living models, an approach that allows precise dissection of the molecular drivers of tumor progression. This methodology is crucial in distinguishing which genetic aberrations are cancer’s true vulnerabilities, offering promising avenues for the development of targeted therapies.

What sets Dr. Papagiannakopoulos apart is his integrative focus that spans metabolism and immunology, fields traditionally studied in isolation. His work elucidates how metabolic rewiring in tumor cells not only supports survival but actively shapes the immune milieu within and beyond the tumor microenvironment. By understanding these dynamic interactions, his research opens the door to manipulating tumor metabolism and immune responses concurrently, a strategy that could revolutionize anti-cancer treatments.

A novel dimension of his research investigates the crosstalk between tumors and the nervous system. Dr. Papagiannakopoulos and his team explore how cancer cells influence brain and peripheral nerve functions to modulate tumor growth, metabolic pathways, and immune system behavior. These interactions have significant clinical implications as they contribute to the cachexia syndrome frequently observed in cancer patients—manifesting as fatigue, anorexia, and severe weight loss—and currently represent a major therapeutic challenge.

Dr. Papagiannakopoulos’s involvement in the InteroCANCEption project, backed by a prestigious Cancer Grand Challenges grant, aims to decode the mechanisms by which the nervous system senses and responds to cancer throughout the body. This systemic approach to cancer biology underscores the emerging paradigm that cancer should be understood not only as a cellular and genetic disease but also as a complex disorder modulated by whole-body physiological networks.

Commenting on the appointment, Salk Institute President Gerald Joyce highlighted Dr. Papagiannakopoulos’s talent for bridging fundamental cancer biology with innovative, interdisciplinary strategies. Joyce emphasized that this alignment with Salk’s culture of curiosity-driven research and collaboration exemplifies the Institute’s mission to pioneer foundational science with the potential to yield transformative clinical breakthroughs.

Dr. Papagiannakopoulos expressed enthusiasm about joining the Salk Institute, citing its unique environment where high-risk, high-reward science thrives. He underscored the significance of integrating his expertise with the existing strengths in cancer immunobiology, metabolism, and neurobiology at Salk, particularly collaboration opportunities with the NOMIS Center and neuroscientists focusing on how cancer intersects with systemic physiology.

Among his groundbreaking contributions, Dr. Papagiannakopoulos’s recent publications in Nature unveiled therapeutic potentials by targeting proteins involved in ferroptosis resistance and immune evasion in lung and pancreatic cancer models. Ferroptosis, a regulated form of cell death driven by iron-dependent lipid peroxidation, represents an Achilles’ heel for certain tumors—disabling mechanisms that prevent ferroptosis can trigger cancer cell death. Similarly, inhibiting proteins that suppress anti-tumor immune responses unveils new immunotherapeutic strategies that could complement existing treatments, broadening the arsenal against aggressive cancers.

Dr. Papagiannakopoulos’s academic journey is distinguished by rigorous training, beginning with a Bachelor’s degree in Molecular Genetics from the University of Sussex, followed by a PhD in Molecular and Cellular Biology at the University of California, Santa Barbara. His postdoctoral work at MIT sharpened his expertise in genome engineering techniques and in vivo cancer modeling. Throughout his career, his innovative research has attracted significant funding from federal and philanthropic sources, including the National Institutes of Health and the American Cancer Society.

At the Salk Institute, Dr. Papagiannakopoulos aims to establish a multidisciplinary research program that emphasizes integrative cancer biology, emphasizing the complex interplay between genetic mutations, cellular metabolism, immune surveillance, and neural regulation. His work will further energize Salk’s Conquering Cancer Initiative, which coordinates researchers across diverse fields to develop innovative strategies targeting lethal cancers, with a focus on lung cancer among others.

Reuben Shaw, PhD, director of Salk’s NCI-Designated Cancer Center, praised Dr. Papagiannakopoulos’s rare blend of experimental prowess and biological insight. Shaw highlighted how his innovative use of in vivo genetic modeling combined with deep knowledge of tumor metabolism and immune responses, along with a novel focus on cancer’s brain-body interactions, will greatly enhance the Center’s mission to identify new cancer vulnerabilities. Beyond research, Papagiannakopoulos is also recognized as a dedicated mentor, poised to inspire the next generation of cancer scientists at Salk.

This appointment signals a bold expansion of Salk’s cancer research capabilities, poised to unravel the multifaceted nature of cancer biology. By converging metabolism, immunology, and neurobiology, Dr. Papagiannakopoulos’s interdisciplinary vision promises not only to accelerate basic scientific understanding but also to accelerate the translation of discoveries into novel, effective therapies, potentially transforming cancer treatment paradigms.

The Salk Institute itself, founded in 1960 by Jonas Salk—the developer of the first safe polio vaccine—continues its mission of pioneering foundational and high-impact biological research. Its commitment to risk-taking, curiosity-driven science remains a beacon for innovation, addressing some of society’s most urgent health challenges, including cancer. Dr. Papagiannakopoulos’s recruitment exemplifies the Institute’s ongoing leadership in marrying foundational science with translational prospects that can change medicine globally.

As Dr. Papagiannakopoulos embarks on this next chapter at Salk, the scientific community eagerly anticipates the groundbreaking discoveries that will emerge from his integrative and visionary approach to cancer biology. These efforts not only deepen our molecular understanding of cancer but also pave pathways toward innovative therapeutic interventions that may one day cure or effectively manage certain cancers that currently pose formidable clinical challenges.

Subject of Research: Cancer biology, tumor metabolism, cancer immunology, tumor-host interactions, cancer neuroscience

Article Title: Salk Institute Welcomes Dr. Thales Papagiannakopoulos to Advance Cancer Research Frontier

News Publication Date: April 2, 2026

Web References:

• Salk Institute: www.salk.edu
• InteroCANCEption Project: Cancer Grand Challenges

References:

• Papagiannakopoulos et al., Nature, recent studies on ferroptosis and anti-tumor immunity (specific citations not provided in source text)

Image Credits: Sim Singh

Keywords: Cancer metabolism, immunology, tumor microenvironment, ferroptosis, genome engineering, nervous system and cancer, tumor-host interactions, Salk Institute, lung cancer, pancreatic cancer, cancer neuroscience, cancer therapy

Cells, as the fundamental units of life, encompass an extraordinary diversity even within ostensibly uniform populations such as tissues or tumor masses. This diversity, or heterogeneity, stems from both genetic mutations that alter DNA sequences and epigenetic modifications that influence gene expression without changing the underlying code. These layers of complexity generate a mosaic of cell behaviors that enable development, adaptation to stress, and, conversely, contribute to disease states such as cancer. The new study led by UZH researchers leverages advanced CRISPR-based genome editing to probe these phenomena with remarkable temporal and spatial resolution.

Central to this breakthrough is the integration of fluorescent markers fused to key proteins involved in DNA replication and the DNA damage response. By genetically engineering cells to express these markers, researchers could visualize and quantitatively track the dynamics of genome duplication and accumulation of heritable DNA damage in living cells through successive generations. This approach surpasses traditional snapshot assays by permitting real-time follow-up of the same cellular lineages as they evolve, divide, and differentiate under various stress conditions.

Through sophisticated microscopy combined with computer-assisted tracking software, the team followed the progeny of individual cancer cells, capturing the onset, progression, and resolution of DNA replication events alongside DNA damage signals. One of the most striking findings was that after exposure to stress, daughter cells derived from a single mother cell no longer behaved synchronously. Instead, they exhibited pronounced divergences in DNA replication timing and cell cycle regulation, indicating that stress-induced perturbations are propagated—and even amplified—across multiple generations.

This desynchronization among sibling cells under stress sheds light on the mechanisms by which cellular heterogeneity is established and maintained within tumors. Differences in DNA replication kinetics and cell cycle protein production suggest that cells may adopt divergent trajectories, potentially leading to subpopulations with distinct functional capacities and differential responses to therapies. Such intratumoral heterogeneity is a recognized obstacle to effective cancer treatment, as resistant clones can emerge and drive relapse.

Delving deeper, the study elucidates the origins of polyploidy—a state wherein cells acquire multiple copies of the entire genome. Polyploidy notably increases genomic complexity and is frequently observed in aggressive cancers, where it facilitates adaptation and survival. With the aid of multigenerational tracking, the UZH group identified several pathways leading to polyploidy, each imparting unique effects on genomic stability and cell fitness. These insights underscore that not all polyploidization events are equivalent; their specific mechanisms could influence the evolutionary trajectories of cancer cell populations.

Importantly, the comprehensive integration of real-time imaging data with endpoint molecular analyses allowed the researchers to correlate dynamic processes with lasting cellular outcomes. DNA damage incurred in one generation was found to have heritable effects manifested in later progeny, reinforcing the concept that stress responses are not transient but shape the phenotypic landscape over time. These findings challenge the traditional view of cell lineages as mere replicates and position them as dynamic entities with cumulative memory of past insults.

From a methodological standpoint, the fusion of CRISPR-mediated genome editing with advanced live-cell imaging represents a powerful platform for future studies. It enables high-resolution dissection of complex biological phenomena beyond bulk measurements, capturing single-cell nuances essential for understanding development, disease progression, and therapeutic resistance. The researchers also highlight the potential for automation and artificial intelligence to manage and interpret the vast data generated by such high-throughput single-cell analyses, an indispensable advance given the scale of cellular heterogeneity.

The implications of this work extend beyond academic interest. By defining how genetic and epigenetic heterogeneity develop and persist, the study paves the way for interventions that could manipulate these processes to improve cancer treatment. For example, controlling the pathways leading to polyploidy or enhancing the fidelity of DNA damage responses might render tumor cells more vulnerable to existing therapies. Tailoring treatments based on lineage-specific vulnerabilities could represent a paradigm shift toward more personalized and effective oncology.

This research marks a significant milestone, revealing just the cusp of a deeper understanding of cellular complexity. As Professor Matthias Altmeyer and his team continue refining their methodologies, the promise of unraveling the “tip of the iceberg” becomes ever more tangible. The marriage of molecular genetics, live-cell imaging, and computational analysis is set to transform our grasp of biology at its most fundamental level, with profound repercussions for medicine and biotechnology.

In conclusion, the UZH study offers a detailed blueprint of how cellular heterogeneity arises and is perpetuated through generations, spotlighting the intricate interplay between DNA replication fidelity, damage inheritance, and stress responses. It challenges existing paradigms by demonstrating heritability of stress-induced variations and elucidates the multifaceted origins of polyploidy linked to cancer resilience. This innovative approach sets a new standard for cellular lineage tracing and provides an invaluable framework for future research aiming to conquer the complexities of tumor evolution and therapeutic resistance.

—

Subject of Research: Cells

Article Title: Andreas Panagopoulos, Merula Stout et al. Multigenerational cell tracking of DNA replication and heritable DNA damage. Nature. 21 May 2025. DOI: 10.1038/s41586-025-08986-0

News Publication Date: 21-May-2025

Web References: http://dx.doi.org/10.1038/s41586-025-08986-0

References: Andreas Panagopoulos, Merula Stout et al. Multigenerational cell tracking of DNA replication and heritable DNA damage. Nature. 21 May 2025. DOI: 10.1038/s41586-025-08986-0

Image Credits: Andreas Panagopoulos, Merula Stout et al.

Keywords: Tumor cells, Cancer cell lines, Live cells, Daughter cells, Molecular genetics, DNA damage, DNA replication, Genetic engineering